CClinicalTrials.gg
TerminatedNCT01136668Updated Jun 8, 2021Results posted

Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery

An interventional study of Transversus Abdominis Plane Block and Standard in Anesthesia and Ostomy, sponsored by The Hospital for Sick Children. Terminated at 1 site in Canada. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Treatment

Why this study was terminated
Unable to recruit adequate number of subjects
Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
3 Months to 18 Years
Sex
All
01

Study summary

The primary objective of this study is to determine if the use of Transversus Abdominis Plane (TAP) blocks reduce early postoperative opioid requirements.

Read the detailed description

Revision or closure of ostomy is a common elective surgical procedure at The Hospital for Sick Children. A retrospective audit conducted at SickKids demonstrated significant intraoperative opioid use and significant requirements for rescue opioids in recovery.

Concerns exist regarding the relative merits of opioid use in abdominal surgery. Opioids may decrease bowel motility leading to the increased incidence and duration of postoperative ileus. They may be associated with increased rates of post-operative nausea and vomiting and pruritus. Lastly children may under-report their pain or pain may not be recognized by medical staff leading to inadequate provision of analgesia. This suggests that the use of a regional technique may benefit children undergoing revision of ostomy.

02

Conditions studied

  • Anesthesia
  • Ostomy

Keywords

  • pediatrics
  • Transversus Abdominis Plane Block
  • Ostomy Surgery
  • Anesthesia
  • Regional Anesthetic
03

In context

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 568 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • children undergoing revision or closure of ostomy
  • American Society of Anesthesiologists Classification 1-3.
  • age ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • children undergoing an additional surgical procedure (e.g. circumcision) at an anatomical location not covered by a one-sided/ unilateral TAP block, during the same anesthetic
  • children in whom a TAP block is contraindicated, i.e. surgical scar or distorted anatomy at the site of injection
  • postoperative admission to the intensive care unit
  • children with a known allergy to bupivacaine
  • children with a history of chronic abdominal pain
  • use of opioid analgesics prior to surgery
  • pregnancy
  • impaired renal function
  • impaired hepatic function
  • known impaired cardiac function
  • hypersensitivity to sodium metabisulfite
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Treatment group

    Bupivacine-TAP block

    Procedure: Transversus Abdominis Plane Block

  • Active comparator
    Control Group

    Bupivacaine- wound infiltration

    Procedure: Standard

Interventions

  • ProcedureTransversus Abdominis Plane Block

    A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.

  • ProcedureStandard

    Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.

06

What researchers measure

Primary outcomes

  1. Morphine Requirement

    The primary endpoint will be the proportion of children in each group requiring two or more (≥ 2) boluses of morphine in the PACU.

    Time frame: within the first 48 hours after surgery

07

Results

Posted Jun 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneTreatment GroupControl Group
Started76
Completed76
Not completed00

Outcome measures

PrimaryMorphine Requirement

The primary endpoint will be the proportion of children in each group requiring two or more (≥ 2) boluses of morphine in the PACU.

Time frame:
within the first 48 hours after surgery

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group0/7 (0%)0/7 (0%)0/7 (0%)
Control Group0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment GroupControl GroupTotal
Mean2 ± 27 ± 115 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)Treatment GroupControl GroupTotal
Female235
Male538
08

Study locations

1 site
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01136668
Lead sponsor
The Hospital for Sick Children
Responsible party
Jason Hayes (Staff Anesthesiologist, The Hospital for Sick Children) — Principal investigator
First posted
Jun 3, 2010
Start date
Apr 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Jun 8, 2021
Last update
Jun 8, 2021

Study contacts

Jason Hayes, MD
principal investigator · The Hospital for Sick Children, Toronto Canada

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion